The company made the announcement before market hours today, 28 January 2013.
Meanwhile, the BSE Sensex was up 19.78 points or 0.1% at 20,123.31.
On BSE, 6,431 shares were traded in the counter as against average daily volume of 70,670 shares in the past two weeks.
Also Read
The stock hit a high of Rs 527.15 and a low of Rs 514.90 so far during the day.
Glenmark Generics Inc., USA, a subsidiary of Glenmark Generics (GGL), has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for Mupirocin Calcium Cream USP, 2%. Glenmark will commence shipping the drug immediately, the company said in a statement. Mupirocin Calcium Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length of 100 square cm in area) due to susceptible strain of S. aureus anad S. pyogenes, Glenmark said in a statement.
Based on IMS Health sales data, Mupirocin Calcium Cream generated sales of $56.5 million in the United States for the 12 months ended September 2012, Glenmark said in a statement.
Glenmark's current portfolio consists of 83 products authorized for distribution in the United States marketplace and 46 ANDAs pending approval with the USFDA, the company said. In addition to these internal filings, GGL continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio, Glenmark said in a statement.
Glenmark Generics (GGL) is a subsidiary of Glenmark Pharmaceuticals. It has established presence in North America and developing an European Union (EU) presence. It primarily sells FDF products in the US and the EU, as well as its oncology FDF products in South America. The company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.
Glenmark Pharmaceuticals' consolidated net profit jumped 177% to Rs 156.75 crore on 18.9% growth in net sales to Rs 1255.19 crore in Q2 September 2012 over Q2 September 2011. The company unveils Q3 December 2012 results on 29 January 2013.
Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). The company has a significant presence in branded generics markets across emerging economies including India. The company, along with its subsidiary, has 13 manufacturing facilities in four countries and has five R&D centers. Its subsidiary, Glenmark Generics services the requirements of the US and Western Europe generic markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.
Powered by Capital Market - Live News